Abstract/Details

Signaling of the pleiotrophin growth factor through the anaplastic lymphoma kinase receptor: Studies on mechanism of action, biological activity and inhibitors


2009 2009

Other formats: Order a copy

Abstract (summary)

Pleiotrophin (PTN) is a heparin-binding growth factor that can support tumor growth, invasion, angiogenesis, and metastasis, and is highly expressed in several types of cancers. The mechanism of action responsible for mediating its effects, however, is still controversial. Our laboratory has shown that PTN binds to and activates the anaplastic lymphoma kinase (ALK) receptor, a member of the insulin receptor superfamily. A parallel mechanism of ALK activation is through PTN binding and inactivation of the protein tyrosine phosphatase receptor ζ (Ptprz). Understanding the mechanism of PTN’s biological effect is of importance for the treatment of cancers that depend on this growth factor.

This dissertation demonstrates the role of the ALK receptor for the biological activity of PTN. Two different anti-ALK antibodies, a mouse monoclonal IgG and a human single-chain variable IgG fragment, inhibited the PTN-mediated effects on signaling in neuroblastoma and glioblastoma cells. Furthermore, an ALK kinase inhibitor blocked PTN-mediated cellular signaling and growth of adrenal carcinoma and neuroblastoma cells. The presence of Ptprz did not result in a significant effect on the PTN-ALK signaling axis. However, our findings suggest that the Ptprz pathway can crosstalk with the PTN-ALK axis at the level of p38 MAPK in glioblastoma cells.

We have described the significance for ALK in mediating the biological activity of PTN. Additionally, the ALK receptor has been described to be necessary for the growth of neuroblastoma cells, irrespective of its ligands. Thus, targeting the ALK receptor under both of these conditions may prove to be effective in the treatment of cancers utilizing the PTN-ALK axis. This dissertation further characterizes the ability of anti-ALK antibodies to block ALK activation, and identifies novel small molecule inhibitors capable of inhibiting ALK kinase activity. We show that the anti-ALK monoclonal IgG binds to the surface of ALK-expressing neuroblastoma cells and inhibits their growth. Furthermore, we characterize a previously developed kinase inhibitor as effective against ALK receptor activation. This drug inhibits PTN-mediated ALK activation and downstream signaling, resulting in the abrogation of neuroblastoma cell growth and PTN-induced adrenal carcinoma cell growth and soft agar colony formation.

Indexing (details)


Subject
Molecular biology;
Cellular biology
Classification
0307: Molecular biology
0379: Cellular biology
Identifier / keyword
Biological sciences; Anaplastic lymphoma kinase; Pleiotrophin
Title
Signaling of the pleiotrophin growth factor through the anaplastic lymphoma kinase receptor: Studies on mechanism of action, biological activity and inhibitors
Author
Kodack, David Philip
Number of pages
217
Publication year
2009
Degree date
2009
School code
0076
Source
DAI-B 70/03, Dissertation Abstracts International
Place of publication
Ann Arbor
Country of publication
United States
ISBN
9781109084061
Advisor
Wellstein, Anton
Committee member
Riegel, Anna T.; Toretsky, Jeff A.; Uren, Aykut; Wolfe, Barry B.
University/institution
Georgetown University
Department
Pharmacology
University location
United States -- District of Columbia
Degree
Ph.D.
Source type
Dissertations & Theses
Language
English
Document type
Dissertation/Thesis
Dissertation/thesis number
3350434
ProQuest document ID
304883445
Copyright
Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Document URL
http://search.proquest.com/docview/304883445/abstract
Access the complete full text

You can get the full text of this document if it is part of your institution's ProQuest subscription.

Try one of the following:

  • Connect to ProQuest through your library network and search for the document from there.
  • Request the document from your library.
  • Go to the ProQuest login page and enter a ProQuest or My Research username / password.